Senescence and telomere shortening induced by novel potent G-quadruplex interactive agents, quindoline derivatives, in human cancer cell lines

Oncogene

Volumn 25, Issue 4, 2006, Pages 503-511

  Zhou, J M ^a   Zhu, X F ^a   Lu, Y J ^b   Deng, R ^a   Huang, Z S ^b   Mei, Y P ^a   Wang, Y ^a   Huang, W L ^a   Liu, Z C ^a   Gu, L Q ^b   Zeng, Y X ^a  

^a SUN YAT SEN UNIVERSITY CANCER CENTER   (China)

^b SUN YAT SEN UNIVERSITY   (China)

Author keywords

G quadruplex; Senescence; Telomerase inhibition

Indexed keywords

GUANINE; PROTEIN P16; PROTEIN P21; PROTEIN P27; QUINDOLINE DERIVATIVE; TELOMERASE INHIBITOR; UNCLASSIFIED DRUG;

ARTICLE; CANCER CELL; CANCER CELL CULTURE; CANCER THERAPY; CELL CULTURE; CELL GROWTH; CELL POPULATION; CONCENTRATION (PARAMETERS); CYTOTOXICITY; HUMAN; HUMAN CELL; IC 50; PHENOTYPE; PRIORITY JOURNAL; PROTEIN EXPRESSION; SENESCENCE; TELOMERE;

ALKALOIDS; CELL AGING; CELL LINE, TUMOR; CELL SURVIVAL; CYCLIN-DEPENDENT KINASE INHIBITOR P16; CYCLIN-DEPENDENT KINASE INHIBITOR P21; CYCLIN-DEPENDENT KINASE INHIBITOR P27; DNA; GUANINE; HUMANS; INDOLES; K562 CELLS; NEOPLASMS; QUINOLINES; TELOMERASE; TELOMERE;

EID: 31544441946     PISSN: 09509232     EISSN: 14765594     Source Type: Journal    
DOI: 10.1038/sj.onc.1209067     Document Type: Article

References (41)

1. Bierer DE, Dubenko LG, Zhang P, Lu Q, Imbach PA, Garofalo AW et al. (1998). J Med Chem 41: 2754-2764.
2. Blackburn EH. (1991). Nature 350: 569-573.
3. Blackburn EH. (2000). Nature 408: 53-56.
4. Blackburn EH. (2001). Cell 106: 661-673.
5. Bonjean K, De Pauw-Gillet MC, Defresne MP, Colson P, Houssier C, Dassonneville L et al. (1998). Biochemistry 37: 5136-5146.
6. Bryan TM, Cech TR. (1999). Curr Opin Cell Biol 11: 318-324.
7. Bryan TM, Englezou A, Dalla-Pozza L, Dunham MA, Reddel RR. (1997). Nat Med 3: 1271-1274.
8. Burger AM, Dai F, Schultes CM, Reszka AP, Moore MJ, Double JA et al. (2005). Cancer Res 65: 1489-1496.
9. Caprio V, Guyen B, Opoku-Boahen Y, Mann J, Gowan SM, Kelland LM et al. (2000). Bioorg Med Chem Lett 10: 2063-2066.
10. der-Sarkissian H, Bacchetti S, Cazes L, Londono-Vallejo JA. (2004). Oncogene 23: 1221-1228.
11. Dixon IM, Lopez F, Esteve JP, Tejera AM, Blasco MA, Pratviel G et al. (2005). Chembiochem 6: 123-132.
12. Dunham MA, Neumann AA, Fasching CL, Reddel RR. (2000). Nat Genet 26: 447-450.
13. Fedoroff OY, Salazar M, Han H, Chemeris VV, Kerwin SM, Hurley LH. (1998). Biochemistry 37: 12367-12374.
14. Feng J, Funk WD, Wang SS, Weinrich SL, Avilion AA, Chiu CP et al. (1995). Science 269: 1236-1241.
15. Gowan SM, Harrison JR, Patterson L, Valenti M, Read MA, Neidle S et al. (2002). Mol Pharmacol 61: 1154-1162.
16. Grand CL, Han H, Munoz RM, Weitman S, Von Hoff DD, Hurley LH et al. (2002). Mol Cancer Ther 1: 565-573.
17. Greider CW. (1996). Annu Rev Biochem 65: 337-365.
18. Hahn WC, Stewart SA, Brooks MW, York SG, Eaton E, Kurachi A et al. (1999). Nat Med 5: 1164-1170.
19. Han H, Hurley LH. (2000). Trends Pharmacol Sci 21: 136-142.
20. Hurley LH, Wheelhouse RT, Sun D, Kerwin SM, Salazar M, Fedoroff OY et al. (2000). Pharmacol Ther 85: 141-158.
21. Ishikawa Y, Yamashita T, Tomisugi Y, Uno T. (2001). Nucleic Acids Res Suppl 1: 107-108.
22. Izbicka E, Wheelhouse RT, Raymond E, Davidson KK, Lawrence RA, Sun D et al. (1999). Cancer Res 59: 639-644.
23. Keith WN, Jeffry Evans TR, Glasspool RM. (2001). J Pathol 195: 404-414.
24. Kelland LR. (2001). Lancet Oncol 2: 95-102.
25. Kerwin SM. (2000). Curr Pharm Des 6: 441-478.
26. Kim NW, Piatyszek MA, Prowse KR, Harley CB, West MD, Ho PL et al. (1994). Science 266: 2011-2015.
27. Lisgarten JN, Coll M, Portugal J, Wright CW, Aymami J. (2002). Nat Struct Biol 9: 57-60.
28. Masutomi K, Yu EY, Khurts S, Ben-Porath I, Currier JL, Metz GB et al. (2003). Cell 114: 241-253.
29. Nakamura TM, Morin GB, Chapman KB, Weinrich SL, Andrews WH, Lingner J et al. (1997). Science 277: 955-959.
30. Neidle S, Parkinson G. (2002). Nat Rev Drug Discov 1: 383-393.
31. Pennarun G, Granotier C, Gauthier LR, Gomez D, Hoffschir F, Mandine E et al. (2005). Oncogene 24: 2917-2928.
32. Perry PJ, Gowan SM, Read MA, Kelland LR, Neidle S. (1999a). Anticancer Drug Des 14: 373-382.
33. Perry PJ, Read MA, Davies RT, Gowan SM, Reszka AP, Wood AA et al. (1999b). J Med Chem 42: 2679-2684.
34. Read M, Harrison RJ, Romagnoli B, Tanious FA, Gowan SH, Reszka AP et al. (2001). Proc Natl Acad Sci USA 98: 4844-4849.
35. Reddel RR. (2000). Carcinogenesis 21: 477-484.
36. Riou JF, Guittat L, Mailliet P, Laoui A, Renou E, Petitgenet O et al. (2002). Proc Natl Acad Sci USA 99: 2672-2677.
37. Schultes CM, Guyen B, Cuesta J, Neidle S. (2004). Bioorg Med Chem Lett 14: 4347-4351.
38. Schwarze SR, Shi Y, Fu VX, Watson PA, Jarrard DF. (2001). Oncogene 20: 8184-8192.
39. Sun D, Thompson B, Cathers BE, Salazar M, Kerwin SM, Trent JO et al. (1997). J Med Chem 40: 2113-2116.
40. Tauchi T, Shin-Ya K, Sashida G, Sumi M, Nakajima A, Shimamoto T et al. (2003). Oncogene 22: 5338-5347.
41. Wong JM, Collins K. (2003). Lancet 362: 983-988.